Having gained over740% from our original penny stock alert before crashing, Cannabis Science (OTCBB: CBIS.OB) is surging again, up 28.7%, to $0.139. The marijuana focused biotech company developing pharmaceutical cannabis products announced Friday that company President and CEO, Dr. Robert Melamede, discussed the “Chronic Future – Killing Cancer” documentary scheduled to premier next week at the Harkins Theater.
Cannabis Science has had some real “moments of glory” for shareholders as the stock price has had only one “extremely volatile” trading sessions this year when the share price reached $0.05 momentarily while on its slow decline from its YTD high of $0.2455.
Subscribe today and get our next stock alert delivered to your inbox FREE.
CBIS had 1,897 executed trades on volume of 29,929,432 shares traded. Volume has been increasing in recent weeks in the OTC Bulletin Board listed stock. The 5-Day Average Volume is 17,435,240 where as the 10-Day Average Volume is 13,726,209.
CBIS has gained 54.44% in the last 5 trading sessions.
The documentary buzz around “Chronic Future – Killing Cancer” has been receiving a lot media coverage by local TV channels, news stations and radio stations. The production hopes to create public awareness related to the use of medical cannabis (marijuana) for killing cancer It will also expose the medical marijuana debate in the documentary.
The CBIS documentary will cover every aspect of the successful use medical cannabis has had with different cancer patients coupled with the unfortunate reality the U.S. government has enforced. The hopes are that the Cannabis Science production will help to pave the way for suffering patients in every state who could benefit from the use of medicinal cannabis for a chronic disease or illness to be able to attain their medicine without fear.
Bottom Line: CBIS is a momentum play with strong marketability with its name and the nature of its business. There is an enormous amount of shares outstanding and aa very large float which makes investing in this penny stock for anything more than a short-term play risky.
CBIS has not abused its brand name with the culture who fuel the drive to legalize marijuana for medical purposes by issuing out press releases. It is truly a good stock to watch which you could almost consider to be similar to the Green Bay Packers stock in the sense that those who are invested in the penny stock long do not necessarily care what it says on the scoreboard today.Share